Myung-Ju Ahn, MD | Authors


Comparing Results for 80 mg versus 160 mg Osimertinib in Advanced EGFR+ NSCLC

May 16, 2019

Myung-Ju Ahn, MD, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, discusses the findings from the AURA LM study, which compared an 80 mg dose of osimertinib with a 160 mg dose in patients with EGFR-positive advanced non–small cell lung cancer with leptomeningeal metastases.